PMID- 19409219
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20211020
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 159
IP  - 4
DP  - 2009 Apr 10
TI  - Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced 
      monoamine depletions: the role of corticosterone.
PG  - 1233-43
LID - 10.1016/j.neuroscience.2009.01.067 [doi]
AB  - Exposure to stress alters the behavioral and neurochemical effects of drugs of 
      abuse. However, it is unknown if chronic stress can affect the serotonergic 
      depletions induced by the psychostimulant drug 3,4-methylenedioxymethamphetamine 
      (MDMA). Rats were exposed to 10 days of chronic unpredictable stress (CUS) which 
      resulted in the predicted elevation of basal plasma corticosterone 
      concentrations. On the 11th day, rats received four challenge doses of MDMA (5 
      mg/kg every 2 h, i.p.) or saline. Five days later, rats were killed and serotonin 
      (5-HT) and dopamine content were measured in the striatum, hippocampus, and 
      frontal cortex. MDMA produced greater depletions of 5-HT in all three brain 
      regions of rats pre-exposed to CUS compared to rats not exposed to CUS. 
      CUS-exposed rats also had an augmented acute hyperthermic response but a similar 
      increase in plasma corticosterone after challenge injections of MDMA compared 
      with non-stressed rats similarly challenged with MDMA. Moreover, CUS-exposed rats 
      exhibited an MDMA-induced depletion of striatal dopamine that was absent in 
      non-stressed rats that received MDMA. To investigate the role of corticosterone 
      in these effects, the corticosterone synthesis inhibitor, metyrapone (50 mg/kg 
      i.p.), was administered prior to each stressor on each of the 10 days of CUS. 
      Metyrapone blocked the chronic stress-induced elevation in basal plasma 
      corticosterone, prevented the enhancement of MDMA-induced hyperthermia, and 
      blocked the enhanced depletions of 5-HT and dopamine in CUS-exposed rats, but had 
      no effect on the acute MDMA-induced increases in plasma corticosterone. These 
      findings suggest that CUS alone can increase the basal level of corticosterone 
      that in turn, plays an important role in enhancing the sensitivity of both 5-HT 
      and dopamine terminals to the hyperthermic and monoamine depleting effects of 
      MDMA without altering the acute corticosterone response to an MDMA challenge.
FAU - Johnson, B N
AU  - Johnson BN
AD  - Department of Pharmacology and Experimental Therapeutics, Laboratory of 
      Neurochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
FAU - Yamamoto, B K
AU  - Yamamoto BK
LA  - eng
GR  - R01 DA016866/DA/NIDA NIH HHS/United States
GR  - R01 DA016866-04/DA/NIDA NIH HHS/United States
GR  - DA016866/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090203
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Serotonin Agents)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - W980KJ009P (Corticosterone)
RN  - ZS9KD92H6V (Metyrapone)
SB  - IM
MH  - Animals
MH  - Body Temperature/drug effects/physiology
MH  - Brain/*drug effects/*physiopathology
MH  - Corpus Striatum/drug effects/physiopathology
MH  - Corticosterone/blood/*metabolism
MH  - Dopamine/metabolism
MH  - Enzyme Inhibitors/administration & dosage
MH  - Fever/chemically induced/physiopathology
MH  - Frontal Lobe/drug effects/physiopathology
MH  - Hippocampus/drug effects/physiopathology
MH  - Male
MH  - Metyrapone/administration & dosage
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/metabolism
MH  - Serotonin Agents/*administration & dosage
MH  - Stress, Psychological/*physiopathology
PMC - PMC2677628
MID - NIHMS94276
EDAT- 2009/05/05 09:00
MHDA- 2009/08/21 09:00
PMCR- 2010/04/10
CRDT- 2009/05/05 09:00
PHST- 2008/10/30 00:00 [received]
PHST- 2009/01/14 00:00 [revised]
PHST- 2009/01/29 00:00 [accepted]
PHST- 2009/05/05 09:00 [entrez]
PHST- 2009/05/05 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
PHST- 2010/04/10 00:00 [pmc-release]
AID - S0306-4522(09)00130-4 [pii]
AID - 10.1016/j.neuroscience.2009.01.067 [doi]
PST - ppublish
SO  - Neuroscience. 2009 Apr 10;159(4):1233-43. doi: 
      10.1016/j.neuroscience.2009.01.067. Epub 2009 Feb 3.